BNET Industries
Market Cap:$921.7M
- Public
- IL
Dow Jones Description
Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based expression system. Protalix's ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is enrolling and treating patients in its pivotal phase III clinical trial in Israel, the United States and other locations for its lead product candidate, prGCD, for its enzyme replacement therapy for Gaucher disease, a lysosomal storage disorder in humans, and has reached an agreement with the United States Food and Drug Administration on the final design of the pivotal phase III clinical trial through the FDA's Special Protocol Assessment (SPA) process. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.
President & CEO
David AviezerPeer Companies
NAICS Code Office Administrative Services: 561110
Recent Events
-
Canaccord Adams Reiterates a 'Buy' on Protalix BioTherapeutics PLX
-
Report: Pfizer may make a bid for Protalix
-
BRIEF: Will Pfizer buy Protalix?: Pfizer representatives have visited Protalix Biotherapeutics in Carmiel in the...
-
Canaccord Adams Starts Protalix BioTherapeutics PLX at Buy
-
Hapoalim Securities Initiates Coverage on Protalix BioTherapeutics PLX with an Outperform; Attractive Entry Point
-
Protalix Biotherapeutics: FDA Fast Track for Gaucher Treatment
-
InterDigital Drops, While Align Climbs
-
UPDATE 1-More woes for Genzyme; rival posts good drug data
News & Analysis
Filter by
protalix biotherapeutics inc. - All News and Analysis
BioMed News Bytes: Protalix, Soligenix
Seeking Alpha
- 2009-10-15
Mike Havrilla submits: On 10/15/09, Protalix BioTherapeutics (AMEX: PLX) announced positive top-line results of a pivotal Phase 3 study of its lead drug candidate, UPLYSO Taliglucerase Alfa in treatment naïve patients diagnosed with Gaucher disease. In the study, UPLYSO met its primary endpoint of mean reduction in spleen volume...
Protalix Wins Orphan Drug Status for Gaucher Disease Treatment
Seeking Alpha
- 2009-09-10
Zacks.com submits: On Tuesday, Protalix BioTherapeutics, Inc. PLX announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to prGCD for the treatment of Gaucher disease, an enzyme disorder that can cause liver and neurological problems. The drug is currently being evaluated in a...
Why Would an Insider Be Selling Protalix Shares Now of All Times?
Seeking Alpha
- 2009-09-02
Shlomi Cohen submits: Among the shares in Israeli companies in my portfolio tracked by "Globes", Protalix Biotherapeutics Inc. (AMEX:PLX) can be expected to attract the most attention over the coming weeks. It is a rare situation in our area - a biotech company that grew from an Office of...
Why I'm Buying Protalix
Seeking Alpha
- 2009-08-19
Shlomi Cohen submits: I'm adding Protalix Biotherapeutics Inc. (AMEX:PLX) to my portfolio at the expense of half my holding in Fundtech (Nasdaq: FNDT), although I continue to believe in Fundtech as a special niche company in financial software. I'm getting into biotechnology again, which, as is well known, is...
Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
- 2008-09-08
CARMIEL, Israel -- Protalix BioTherapeutics, Inc. (Amex: PLX), today announced that its board of directors has set the close of business on October 2, 2008, as the record date for shareholders entitled to receive notice of, and to vote at, the Company's 2008 Annual Meeting of Shareholders. It is currently...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| David Aviezer | President & CEO |
| Yossi Maimon | Cfo, Treasurer & Secretary |
| Yoseph Shaaltiel | Executive Vice President, R & D |
| Einat Brill Almon | Vice President, Product Dev |
| Iftah Katz | Vice President, Operations |
| Noah M Silver | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Eli Hurvitz | Chairman |
| Amos Bar-Shalev | Board of Directors |
| Dr. Phillip Frost | Board of Directors |
| Eyal Sheratzki | Board of Directors |
| Professor Roger D. Kornberg | Board of Directors |
| Sharon Toussia-Cohen | Board of Directors |
| Yodfat Harel Gross | Board of Directors |
| Zeev Bronfeld | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Protalix Biotherapeutics, Inc. | President & CEO | Current |
| Protalix Biotherapeutics, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Protalix Biotherapeutics, Inc. | Cfo, Treasurer & Secretary | Current |
| Organization | Position | Status |
|---|---|---|
| Protalix Biotherapeutics, Inc. | Executive Vice President, R & D | Current |
| Protalix Biotherapeutics, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Protalix Biotherapeutics, Inc. | Vice President, Product Dev | Current |
| Organization | Position | Status |
|---|---|---|
| Protalix Biotherapeutics, Inc. | Vice President, Operations | Current |
| Organization | Position | Status |
|---|---|---|
| Protalix Biotherapeutics, Inc. | Chairman | Current |
| Organization | Position | Status |
|---|---|---|
| Protalix Biotherapeutics, Inc. | Board of Directors | Current |
Phillip Frost, M.D. Dr. Frost became the CEO and Chairman of OPKO Health, Inc. upon the consummation of the merger of Acuity Pharmaceuticals Inc., Froptix Corporation and eXegenics, Inc. on March 27, 2007 (referred to as the Acquisition ). Dr. Frost was named the Vice Chairman of the Board of Teva Pharmaceutical Industries, Limited (NasdaqGS:TEVA), or Teva, in January 2006 when Teva acquired IVAX Corporation, or IVAX. Dr. Frost had served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation since 1987. He was Chairman of the Department of Dermatology at Mt. Sinai Medical Center of Greater Miami, Miami Beach, Florida from 1972 to 1986. Dr. Frost was Chairman of the Board of Directors of Key Pharmaceuticals, Inc. from 1972 until the acquisition of Key Pharmaceuticals by Schering Plough Corporation in 1986. Dr. Frost was named Chairman of the Board of Ladenburg Thalmann Financial Services Inc. (NYSE Amex: LTS), an investment banking, asset management, and securities brokerage firm providing services through its principal operating subsidiary, Ladenburg Thalmann & Co. Inc., in July 2006 and has been a director of Ladenburg Thalmann since March 2005. Dr. Frost also serves as Chairman of the Board of Directors of Ideation Acquisition Corp., a special purpose acquisition company formed for the purpose of acquiring businesses in digital media (NYSE Amex: IDI), Modigene Inc., a development stage biopharmaceutical company (OTCBB: MODG), and Castle Brands, a developer and marketer of premium brand spirits (NYSE Amex: ROX). He serves on the Board of Regents of the Smithsonian Institution, as a member of the Board of Trustees of the University of Miami, a Trustee of each of the Scripps Research Institutes, the Miami Jewish Home for the Aged, and the Mount Sinai Medical Center. Dr. Frost is also a director of Continucare Corporation, a provider of outpatient healthcare and home healthcare services (NYSE Amex: CNU), and Northrop Grumman Corp., a global defense and aerospace company (NYSE: NOC).
| Organization | Position | Status |
|---|---|---|
| Opko Health, Inc. | CEO | Current |
| Peregrine Ventures | Terms & Conditions | General Partner & Investment Committee Member | Current |
| University of Miami | Trustee | Current |
| The Scripps Research Institute | Trustee | Current |
| Ladenburg Thalmann Financial Services Inc. | Chairman of the Board of Directors | Current |
| Pzk | Chairman | Current |
| Opko Health, Inc. | Chairman | Current |
| Modigene Inc. | Chairman of The Board of Directors | Current |
| Ideation Acquisition Corp. | Chairman of the Board of Directors | Current |
| Ladenburg Thalmann & Co., Inc. | Director | Current |
| Cellular Technical Services Co, Inc. | Director | Current |
| Protalix Biotherapeutics, Inc. | Board of Directors | Current |
| Continucare Corporation | Director | Current |
| The Regents | Board of Directors | Current |
| The American Stock Exchange LLC | Member, Board of Governors | Current |
| Castle Brands Inc. | Board of Directors | Current |
| Peregrine Ventures | Terms & Conditions | Board of Directors | Current |
| IVAX Diagnostics, Inc. | Board of Directors | Current |
| The Frost Group | Board of Directors | Current |
| Teva Pharmaceutical Industries Ltd. | Vice Chairman of the Board of Directors | Current |
| Northrop Grumman Corporation | Board of Directors | Current |
| Continucare Corporation | Vice Chairman, Board of Directors | Current |
| IVAX Corporation | CEO | Former |
| IVAX Corporation | President | Former |
| IVAX Corporation | Chairman, Board of Directors | Former |
| University of Miami | Chairman, Board of Trustees | Former |
| Teva Pharmaceutical Industries Ltd. | Chairman, Board of Directors | Former |
| Modigene Inc. | Board of Directors | Former |
| Ladenburg Thalmann Financial Services Inc. | Board of Directors | Former |
| Albert Einstein College | M.D. | Former |
| The American Stock Exchange LLC | member | Former |
| Organization | Position | Status |
|---|---|---|
| Protalix Biotherapeutics, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Quikbyte Software Inc | Vice President, Secretary & Treasurer | Current |
| Protalix Biotherapeutics, Inc. | Director | Current |
| Quikbyte Software Inc | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Stanford University School of Medicine | Professor of Structural Biology | Current |
| Stanford University | Winzer Professor of Medicine, Department of Structural Biology | Current |
| Pacific Biosciences | Professor of Structural Biology, Stanford University | Current |
| Compugen, Ltd. | Current | |
| Teva Pharmaceutical Industries Ltd. | Board of Directors | Current |
| Protalix Biotherapeutics, Inc. | Board of Directors | Current |
| Epiphany Biosciences, Inc. | Board of Directors | Current |
| Sciences, Inc | Board of Directors | Current |
| National Academy of Sciences | Member | Current |
| Harvard Medical School | Professor | Former |
| Stanford University | PhD | Former |
| Harvard University | B.S. In Chemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Protalix Biotherapeutics, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Protalix Biotherapeutics, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Protalix Biotherapeutics, Inc. | Board of Directors | Current |
Executive News
-
Opko narrows losses
-
Protalix Biotherapeutics to Participate in Three International Healthcare Conferences
| Volume | 1,168,678 |
| Shares Outstanding | 77.2M |
| Market Cap | 921.7M |
| Year High | 12.50 |
| Year Low | 0.96 |
| Earnings Per Share | -0.32 |
| P/E Ratio | N/A |
| Dividend | 0.00 |
| Yield | 0.00 |
Industry Transcripts by Seeking Alpha
-
Thomas Group, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about TGIS
-
Hewitt Associates Inc. F4Q09 (Qtr End 09/30/09) Earnings Call Transcript
on Nov 10, 2009about HEW
-
Fluor Corporation Q3 2009 Earnings Call Transcript
on Nov 09, 2009about FLR
-
TechTarget, Inc. Q3 2009 Earnings Call Transcript
on Nov 09, 2009about TTGT
-
ENGlobal Corporation Q3 2009 Earnings Call Transcript.
on Nov 09, 2009about ENG
IndustryTop Rated
